Last reviewed · How we verify
Aspergillosis — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Isauvuconazole group | isauvuconazole-group | Pfizer | Echinocandin | β-(1,3)-D-glucan synthase | Not yet launched | |
| Cresemba | ISAVUCONAZONIUM | Astellas Pharma | Azole Antifungal | ATP-binding cassette sub-family G member 2 | 2015-01-01 | |
| Sporanox | itraconazole | Sebela Ireland Ltd | Azole Antifungal [EPC] | C-X-C chemokine receptor type 1 | 1992-01-01 | |
| Abelcet | AMPHOTERICIN B | Astellas Pharma | Lipid-based Polyene Antifungal [EPC] | 1964-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Astellas Pharma · 2 drugs in Aspergillosis
- Pfizer · 1 drug in Aspergillosis
- Sebela Ireland Ltd · 1 drug in Aspergillosis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Aspergillosis:
- Aspergillosis treatment updates — RSS
- Aspergillosis treatment updates — Atom
- Aspergillosis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Aspergillosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/aspergillosis. Accessed 2026-06-10.
Related
- Aspergillosis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing